To find an answer, Jonathan Engler finds following the money usually gets closer to the truth. “In this regard … before 2020 pharma / biotech was struggling with a dearth of new ideas and many blockbuster products under pressure from pending patent expirations,” he notes.
This leads to a serious question which needs to be asked.
The mRNA platform transfects cells throughout the body (since the lipid nanoparticles, LNPs, go everywhere) and generates foreign protein4 in uncontrolled and uncontrollable quantities for an unknown and uncontrollable duration.
Since transfected cells then get destroyed by the body’s immune system, this is inherently dangerous.5
However, there was always a much safer means of priming the body against specific viral proteins.
Protein subunit vaccines – e.g. the recombinant hepatitis B vaccine – have been around for decades. They use yeast cells to make the antigen. Their use involves the injection of a fixed and controlled quantity of the antigen. Much is known about their safety and the “known unknowns” are much less likely to be consequential to safety.
So: why was the mRNA platform selected instead?
They could have made the chosen viral protein using the existing subunit manufacturing technology....<<<Read More>>>...